Stifel Nicolaus Boosts Edwards Lifesciences (NYSE:EW) Price Target to $85.00

Edwards Lifesciences (NYSE:EW) had its price target boosted by equities research analysts at Stifel Nicolaus from $83.00 to $85.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “hold” rating on the medical research company’s stock. Stifel Nicolaus’ target price would suggest a potential downside of 1.65% from the company’s current price.

Other analysts have also recently issued reports about the stock. Royal Bank of Canada upped their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Evercore ISI upped their target price on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Finally, StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.33.

Edwards Lifesciences Stock Down 1.8 %

Shares of Edwards Lifesciences stock opened at $86.43 on Friday. The company has a market cap of $52.02 billion, a price-to-earnings ratio of 37.25, a price-to-earnings-growth ratio of 4.36 and a beta of 1.05. The company’s 50 day moving average is $90.28 and its 200 day moving average is $78.89. Edwards Lifesciences has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Research analysts anticipate that Edwards Lifesciences will post 2.76 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the transaction, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $94.89, for a total transaction of $688,426.95. Following the completion of the transaction, the chief financial officer now owns 19,074 shares in the company, valued at $1,809,931.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Heisz Leslie Stone sold 7,056 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the transaction, the director now owns 26,980 shares of the company’s stock, valued at approximately $2,332,421. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 194,004 shares of company stock valued at $17,166,254. Corporate insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently bought and sold shares of the business. Caprock Group LLC lifted its holdings in shares of Edwards Lifesciences by 4.8% in the 3rd quarter. Caprock Group LLC now owns 8,611 shares of the medical research company’s stock worth $597,000 after acquiring an additional 392 shares during the last quarter. Oak Thistle LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $700,000. Czech National Bank lifted its holdings in shares of Edwards Lifesciences by 48.1% in the 3rd quarter. Czech National Bank now owns 106,252 shares of the medical research company’s stock worth $7,361,000 after acquiring an additional 34,487 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in shares of Edwards Lifesciences by 0.5% in the 3rd quarter. Asset Management One Co. Ltd. now owns 323,224 shares of the medical research company’s stock worth $22,393,000 after acquiring an additional 1,622 shares during the last quarter. Finally, Connecticut Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 66.7% in the 3rd quarter. Connecticut Wealth Management LLC now owns 9,960 shares of the medical research company’s stock worth $690,000 after acquiring an additional 3,985 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.